tradingkey.logo

Envista Q4 revenue up 10.8%, beats estimates

ReutersFeb 5, 2026 9:19 PM


Overview

  • Dental industry leader's Q4 revenue grew 10.8%, beating analyst expectations

  • Adjusted EPS for Q4 rose 58% yr/yr, beating analyst expectations

  • Company returned $166 mln to shareholders via share repurchases in 2025


Outlook

  • Envista projects 2026 core sales growth between 2% and 4%

  • Company expects adjusted EBITDA growth of 7% to 13% for 2026

  • Envista forecasts adjusted EPS of $1.35 to $1.45 for 2026


Result Drivers

  • CORE SALES GROWTH - Envista reported 10.8% core sales growth in Q4 2025, driven by positive performance across all major businesses and geographies

  • CUSTOMER TRAINING & R&D - Co increased customer training by 30% in 2025 and made double-digit R&D investments to support innovation-led growth

  • OPERATIONAL IMPROVEMENTS - Envista Business System helped reduce G&A expenses by 10% in 2025 and improve Spark's operating margin


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$750.60 mln

$679.95 mln (13 Analysts)

Q4 Adjusted EPS

Beat

$0.38

$0.32 (15 Analysts)

Q4 EPS

$0.20

Q4 Adjusted Net Income

$63 mln

Q4 Net Income

$33 mln

Q4 Adjusted EBITDA

$111 mln

Q4 Gross Profit

$410.60 mln

Q4 Operating Profit

$73.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Envista Holdings Corp is $24.00, about 1.4% above its February 4 closing price of $23.66

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nPn250QjXa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI